

Ovidiu Chioncel

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9775231/ovidiu-chioncel-publications-by-year.pdf>

Version: 2024-04-10

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

132 papers	20,660 citations	41 h-index	143 g-index
162 ext. papers	30,747 ext. citations	8 avg, IF	5.97 L-index

#	Paper	IF	Citations
132	Preventing heart failure: a position paper of the Heart Failure Association in collaboration with the European Association of Preventive Cardiology.. <i>European Journal of Heart Failure</i> , 2022 , 24, 143-168	12.3	7
131	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC.. <i>European Journal of Heart Failure</i> , 2022 , 24, 4-131	12.3	50
130	Rare Cause of Severe Mitral Regurgitation after TAVI: Case Report and Literature Review.. <i>Medicina (Lithuania)</i> , 2022 , 58,	3.1	0
129	Overcoming the Limits of Ejection Fraction and Ventricular-Arterial Coupling in Heart Failure.. <i>Frontiers in Cardiovascular Medicine</i> , 2021 , 8, 750965	5.4	2
128	A comprehensive characterization of acute heart failure with preserved vs. mildly reduced vs. reduced ejection fraction - insights from the ESC-HFA EORP Heart Failure Long-Term Registry.. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	4
127	Navigating between Scylla and Charybdis: challenges and strategies for implementing guideline-directed medical treatment in heart failure with reduced ejection fraction. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
126	Pathophysiology of Takotsubo syndrome – a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology – Part 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	6
125	Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
124	Factors associated with in-hospital mortality and adverse outcomes during the vulnerable post-discharge phase after the first episode of acute heart failure: results of the NOVICA-2 study. <i>Clinical Research in Cardiology</i> , 2021 , 110, 993-1005	6.1	3
123	Synergistic Impact of Systolic Blood Pressure and Perfusion Status on Mortality in Acute Heart Failure. <i>Circulation: Heart Failure</i> , 2021 , 14, e007347	7.6	4
122	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. <i>European Journal of Heart Failure</i> , 2021 , 23, 527-540	12.3	10
121	The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019. <i>European Journal of Heart Failure</i> , 2021 , 23, 906-914	12.3	28
120	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 872-881	12.3	41
119	Echocardiographic Hemodynamic Heterogeneity of Advanced Heart Failure Patients as Compared to Patients with Pre-Heart Failure – <i>Revista Romana De Cardiologie</i> , 2021 , 31, 351-359	0.1	
118	Does end-organ dysfunction precede or follow cardiogenic shock in acute decompensated heart failure? The two-faced Janus. Reply. <i>European Journal of Heart Failure</i> , 2021 , 23, 197-198	12.3	0
117	Self-care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2021 , 23, 157-174	12.3	41
116	Guidance on the management of left ventricular assist device (LVAD) supported patients for the non-LVAD specialist healthcare provider: executive summary. <i>European Journal of Heart Failure</i> , 2021 , 23, 1597-1609	12.3	6

115	Outcomes of patients with heart failure with preserved ejection fraction discharged on treatment with neurohormonal antagonists after an episode of decompensation. <i>European Journal of Internal Medicine</i> , 2021 , 94, 73-84	3.9	0
114	2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. <i>European Heart Journal</i> , 2021 , 42, 3599-3726	9.5	875
113	Heart Failure Association of the European Society of Cardiology position paper on the management of left ventricular assist device-supported patients for the non-left ventricular assist device specialist healthcare provider: Part 2: at the emergency department. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
112	HFA of the ESC Position paper on the management of LVAD supported patients for the non LVAD specialist healthcare provider Part 1: Introduction and at the non-hospital settings in the community. <i>ESC Heart Failure</i> , 2021 ,	3.7	2
111	Amended STRONG-HF study design. <i>European Journal of Heart Failure</i> , 2021 , 23, 1981-1982	12.3	0
110	HFA of the ESC position paper on the management of LVAD-supported patients for the non-LVAD specialist healthcare provider Part 3: at the hospital and discharge. <i>ESC Heart Failure</i> , 2021 ,	3.7	3
109	Percutaneous Closure of Gerbode Defect Type II Post-TAVR With Amplatzer Muscular VSD Occluder. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, e229-e230	5	0
108	Regional variation of effects of new antidiabetic medications in cardiovascular outcome trials. <i>American Heart Journal</i> , 2021 , 240, 73-80	4.9	0
107	The FAST-FURO study: effect of very early administration of intravenous furosemide in the prehospital setting to patients with acute heart failure attending the emergency department. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021 , 10, 487-496	4.3	2
106	Pathophysiology of Takotsubo Syndrome - a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of Cardiology - Part 1: Overview and the central role for catecholamines and sympathetic activation. <i>European Journal of Heart Failure</i> , 2021 ,	12.3	3
105	Successful concomitant open surgical repair of aortic arch pseudoaneurysm and percutaneous myocardial revascularization in a high risk patient: A case report. <i>International Journal of Surgery Case Reports</i> , 2020 , 74, 86-90	0.8	
104	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1815-1828	12.3	127
103	Epidemiology, pathophysiology and contemporary management of cardiogenic shock - a position statement from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1315-1341	12.3	83
102	Sodium-glucose co-transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1495-1503	12.3	56
101	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 1504-1524	12.3	74
100	The Heart Failure Association Atlas: rationale, objectives, and methods. <i>European Journal of Heart Failure</i> , 2020 , 22, 638-645	12.3	13
99	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and high-risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1298-1314	12.3	23
98	Unravelling the interplay between hyperkalaemia, renin-angiotensin-aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC-HFA-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1378-1389	12.3	32

97	Association between loop diuretic dose changes and outcomes in chronic heart failure: observations from the ESC-EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 1424-1437	12.3	13
96	Transseptal Approach for Mitral Valve Replacement in Dextrocardia with Situs Inversus Totalis: A Case Report and Review of the Literature. <i>Heart Surgery Forum</i> , 2020 , 23, E030-E033	0.7	1
95	Microcirculatory Dysfunction in Acute Heart Failure 2020 , 193-221		0
94	Understanding cardiac systolic performance beyond left ventricular ejection fraction 2020 , 1, 75-84		2
93	Sex- and age-related differences in the management and outcomes of chronic heart failure: an analysis of patients from the ESC HFA EORP Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2020 , 22, 92-102	12.3	35
92	Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis. <i>European Journal of Heart Failure</i> , 2020 , 22, 315-329	12.3	16
91	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucose-lowering drugs in patients with heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 196-213	12.3	85
90	European Society of Cardiology: Cardiovascular Disease Statistics 2019. <i>European Heart Journal</i> , 2020 , 41, 12-85	9.5	330
89	Heart Failure Association of the European Society of Cardiology update on sodium-glucose co-transporter 2 inhibitors in heart failure. <i>European Journal of Heart Failure</i> , 2020 , 22, 1984-1986	12.3	44
88	Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2020 , 22, 1866-1882	12.3	61
87	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2020 , 22, 2272-2289	12.3	33
86	Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper. <i>European Journal of Heart Failure</i> , 2020 , 22, 2327-2339	12.3	30
85	The value of a superior vena cava collapsibility index measured with a miniaturized transoesophageal monoplane continuous echocardiography probe to predict fluid responsiveness compared to stroke volume variations in open major vascular surgery: a prospective cohort study. <i>Journal of Clinical Monitoring and Computing</i> , 2020 , 34, 491-499	2	3
84	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
83	2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2020 , 41, 255-323	9.5	1360
82	Mega-trials in heart failure: effects of dilution in examination of new therapies. <i>European Journal of Heart Failure</i> , 2020 , 22, 1698-1707	12.3	6
81	Clinical presentation, aetiology and outcome of infective endocarditis. Results of the ESC-EORP EURO-ENDO (European infective endocarditis) registry: a prospective cohort study. <i>European Heart Journal</i> , 2019 , 40, 3222-3232	9.5	169
80	Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 1169-1186	12.3	325

79	Clinical phenotypes of acute heart failure based on signs and symptoms of perfusion and congestion at emergency department presentation and their relationship with patient management and outcomes. <i>European Journal of Heart Failure</i> , 2019 , 21, 1353-1365	12.3	22
78	Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy. <i>European Journal of Heart Failure</i> , 2019 , 21, 827-843	12.3	107
77	Acute heart failure congestion and perfusion status—Impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2019 , 21, 1338-1352	12.3	62
76	Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2019 , 21, 553-576	12.3	118
75	Safety, Tolerability and efficacy of Rapid Optimization, helped by NT-proBNP and GDF-15, of Heart Failure therapies (STRONG-HF): rationale and design for a multicentre, randomized, parallel-group study. <i>European Journal of Heart Failure</i> , 2019 , 21, 1459-1467	12.3	13
74	Departments involved during the first episode of acute heart failure and subsequent emergency department revisits and rehospitalisations: an outlook through the NOVICA cohort. <i>European Journal of Heart Failure</i> , 2019 , 21, 1231-1244	12.3	14
73	Should providers prescribe sacubitril/valsartan based on trial eligibility, approval indication, or guideline recommendations?. <i>European Journal of Heart Failure</i> , 2019 , 21, 1398-1401	12.3	3
72	Cardiogenic shock in cancer. <i>Heart Failure Reviews</i> , 2019 , 24, 997-1004	5	5
71	Mitral Valve Replacement with Thymectomy in a Patient with Ocular Myasthenia Gravis: Case Report. <i>Heart Surgery Forum</i> , 2019 , 22, E340-E342	0.7	1
70	Successful Management of Unremitting Spasm after Myocardial Revascularization Exclusively with Bilateral Internal Thoracic Arteries in Y-graft Configuration: A Case Report. <i>Heart Surgery Forum</i> , 2019 , 22, E283-E286	0.7	
69	Renal function, electrolytes, and congestion monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019 , 21, M25-M31	1.5	3
68	Therapeutic Advances in the Management of Acute Decompensated Heart Failure. <i>American Journal of Therapeutics</i> , 2019 , 26, e222-e233	1	3
67	Therapeutic Advances in the Management of Cardiogenic Shock. <i>American Journal of Therapeutics</i> , 2019 , 26, e234-e247	1	8
66	Left ventricular function monitoring in heart failure. <i>European Heart Journal Supplements</i> , 2019 , 21, M17-M19	1.5	5
65	World Heart Federation Roadmap for Heart Failure. <i>Global Heart</i> , 2019 , 14, 197-214	2.9	33
64	Acute heart failure: lessons learned, roads ahead. <i>European Journal of Heart Failure</i> , 2018 , 20, 842-850	12.3	13
63	Comprehensive in-hospital monitoring in acute heart failure: applications for clinical practice and future directions for research. A statement from the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2018 , 20, 1081-1099	12.3	40
62	Expanded algorithm for managing patients with acute decompensated heart failure. <i>Heart Failure Reviews</i> , 2018 , 23, 597-607	5	4

61	Lessons learned in acute heart failure. <i>European Journal of Heart Failure</i> , 2018 , 20, 630-641	12.3	19
60	Pre-discharge and early post-discharge troponin elevation among patients hospitalized for heart failure with reduced ejection fraction: findings from the ASTRONAUT trial. <i>European Journal of Heart Failure</i> , 2018 , 20, 281-291	12.3	17
59	Long-term safety of intravenous cardiovascular agents in acute heart failure: results from the European Society of Cardiology Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2018 , 20, 332-341	12.3	49
58	Rationale and Design of a Prospective, Multicenter, Observational Study Evaluating Iron Deficiency in Patients Hospitalized for Heart Failure (FERIC-RO). <i>Romanian Journal of Laboratory Medicine</i> , 2018 , 26, 271-281	0.3	1
57	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 205-218	40	204
56	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2018 , 391, 219-229	40	414
55	Optimal Endpoints of Acute Heart Failure Therapy. <i>American Journal of Therapeutics</i> , 2018 , 25, e465-e474		3
54	The Vulnerable Phase of Heart Failure. <i>American Journal of Therapeutics</i> , 2018 , 25, e456-e464	1	8
53	Improving Postdischarge Outcomes in Acute Heart Failure. <i>American Journal of Therapeutics</i> , 2018 , 25, e475-e486	1	6
52	Mihai Gheorghiade, MD-Life and Concepts. <i>American Journal of Therapeutics</i> , 2018 , 25, e453-e455	1	
51	Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry. <i>JACC: Heart Failure</i> , 2018 , 6, 452-462	7.9	51
50	Clinical phenotypes and outcome of patients hospitalized for acute heart failure: the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1242-1254	12.3	166
49	Organ dysfunction, injury and failure in acute heart failure: from pathophysiology to diagnosis and management. A review on behalf of the Acute Heart Failure Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). <i>European Journal of Heart Failure</i> , 2017 , 19, 821-836	12.3	147
48	Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 1574-1585	12.3	301
47	Inotropes in acute heart failure. <i>Continuing Cardiology Education</i> , 2017 , 3, 107-116		7
46	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 377, 1319-1330	59.2	1122
45	In-hospital and 1-year mortality associated with diabetes in patients with acute heart failure: results from the ESC-HFA Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2017 , 19, 54-65	12.3	92
44	A multifaceted intervention to improve treatment with oral anticoagulants in atrial fibrillation (IMPACT-AF): an international, cluster-randomised trial. <i>Lancet, The</i> , 2017 , 390, 1737-1746	40	106

43	Predictors of Post-discharge Mortality Among Patients Hospitalized for Acute Heart Failure. <i>Cardiac Failure Review</i> , 2017 , 3, 122-129	4.2	18
42	Resuscitation of sudden cardiac death caused by acute epileptic seizures: A case report. <i>Journal of Acute Disease</i> , 2016 , 5, 168-171	0.9	1
41	Serum Osmolality and Postdischarge Outcomes After Hospitalization for Heart Failure. <i>American Journal of Cardiology</i> , 2016 , 117, 1144-50	3	16
40	Epidemiology, pathophysiology, and in-hospital management of pulmonary edema: data from the Romanian Acute Heart Failure Syndromes registry. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 92-104	1.9	14
39	Impact of oral P2Y12 inhibitors on residual thrombus burden and reperfusion indexes in patients with ST-segment elevation myocardial infarction. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 701-6	1.9	3
38	European Society of Cardiology Heart Failure Long-Term Registry (ESC-HF-LT): 1-year follow-up outcomes and differences across regions. <i>European Journal of Heart Failure</i> , 2016 , 18, 613-25	12.3	316
37	Natriuretic peptide-guided management in heart failure. <i>Journal of Cardiovascular Medicine</i> , 2016 , 17, 556-68	1.9	21
36	The bumpy road to drug development for acute heart failure. <i>European Heart Journal Supplements</i> , 2016 , 18, G19-G32	1.5	16
35	ST Segment Elevation Myocardial Infarction Due to Severe Ostial Left Main Stem Stenosis in a Patient with Syphilitic Aortitis. <i>Romanian Journal of Internal Medicine = Revue Roumaine De Medecine Interne</i> , 2016 , 54, 74-9	1.5	2
34	2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. <i>European Heart Journal</i> , 2016 , 37, e166-239	9.5	775 ¹
33	Angina and Future Cardiovascular Events in Stable Patients With Coronary Artery Disease: Insights From the Reduction of Atherothrombosis for Continued Health (REACH) Registry. <i>Journal of the American Heart Association</i> , 2016 , 5,	6	30
32	Changes in Dyspnea Status During Hospitalization and Postdischarge Health-Related Quality of Life in Patients Hospitalized for Heart Failure: Findings From the EVEREST Trial. <i>Circulation: Heart Failure</i> , 2016 , 9,	7.6	14
31	Contemporary management of acute right ventricular failure: a statement from the Heart Failure Association and the Working Group on Pulmonary Circulation and Right Ventricular Function of the European Society of Cardiology. <i>European Journal of Heart Failure</i> , 2016 , 18, 226-41	12.3	292
30	Surgical Management of Type A Acute Aortic Dissection in Patients With Marfan Syndrome: A Single Center Experience. <i>Revista Medico-chirurgicala A Societatii De Medici Si Naturalisti Din Iasi</i> , 2016 , 120, 611-18		3
29	Characteristics of Intensive Care in Patients Hospitalized for Heart Failure in Europe. <i>Heart Failure Clinics</i> , 2015 , 11, 647-56	3.3	6
28	Acute heart failure: the role of focused emergency cardiopulmonary ultrasound in identification and early management. <i>European Journal of Heart Failure</i> , 2015 , 17, 1223-7	12.3	21
27	Pulmonary Oedema-Therapeutic Targets. <i>Cardiac Failure Review</i> , 2015 , 1, 38-45	4.2	6
26	Use of Anticoagulants and Antiplatelet Agents in Stable Outpatients with Coronary Artery Disease and Atrial Fibrillation. International CLARIFY Registry. <i>PLoS ONE</i> , 2015 , 10, e0125164	3.7	9

25	Changes in serum potassium levels during hospitalization in patients with worsening heart failure and reduced ejection fraction (from the EVEREST trial). <i>American Journal of Cardiology</i> , 2015 , 115, 790-6 ³	28
24	Patterns of intensive care unit admissions in patients hospitalized for heart failure: insights from the RO-AHFS registry. <i>Journal of Cardiovascular Medicine</i> , 2015 , 16, 331-40	1.9 12
23	The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. <i>Journal of the American College of Cardiology</i> , 2014 , 63, 1123-1133	15.1 1160
22	Developing therapies for heart failure with preserved ejection fraction: current state and future directions. <i>JACC: Heart Failure</i> , 2014 , 2, 97-112	7.9 213
21	Global perspectives in hospitalized heart failure: regional and ethnic variation in patient characteristics, management, and outcomes. <i>Current Heart Failure Reports</i> , 2014 , 11, 416-27	2.8 30
20	Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). <i>American Journal of Cardiology</i> , 2014 , 114, 1713-21	3 35
19	Mineralocorticoid receptor antagonist use in hospitalized patients with heart failure, reduced ejection fraction, and diabetes mellitus (from the EVEREST Trial). <i>American Journal of Cardiology</i> , 2014 , 114, 743-50	3 8
18	Designing effective drug and device development programs for hospitalized heart failure: a proposal for pretrial registries. <i>American Heart Journal</i> , 2014 , 168, 142-9	4.9 25
17	An unusual association: right atrial myxoma and severe left ventricular dysfunction. Case report and review of the literature. <i>Heart Surgery Forum</i> , 2014 , 17, E285-7	0.7
16	The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. <i>JACC: Heart Failure</i> , 2013 , 1, 488-96	7.9 49
15	The predictive value of transaminases at admission in patients hospitalized for heart failure: findings from the RO-AHFS registry. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2013 , 2, 99-108	4.3 19
14	Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12,440 patients of the ESC Heart Failure Long-Term Registry. <i>European Journal of Heart Failure</i> , 2013 , 15, 1173-84	12.3 388
13	EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2013 , 15, 808-17	12.3 462
12	Heart rate and use of beta-blockers in stable outpatients with coronary artery disease. <i>PLoS ONE</i> , 2012 , 7, e36284	3.7 60
11	The Romanian Acute Heart Failure Syndromes (RO-AHFS) registry. <i>American Heart Journal</i> , 2011 , 162, 142-53.e1	4.9 47
10	EURObservational Research Programme: the Heart Failure Pilot Survey (ESC-HF Pilot). <i>European Journal of Heart Failure</i> , 2010 , 12, 1076-84	12.3 258
9	Rare tumors of the heart--angiosarcoma, pericardial lipoma, leiomyosarcoma. Three case reports. <i>Journal of Medicine and Life</i> , 2010 , 3, 178-82	1.5 2
8	Utilization of levosimendan in the cardiac ICU: case series. <i>Critical Care</i> , 2009 , 13, P168	10.8 78

7	The electrocardiographic abnormalities in highly trained athletes compared to the genetic study related to causes of unexpected sudden cardiac death. <i>Journal of Medicine and Life</i> , 2009 , 2, 361-72	1.5	5
6	Hemodynamic, echocardiographic, and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure. <i>Journal of the American College of Cardiology</i> , 2008 , 51, 2276-85	15.1	113
5	Coronary sinus visualization by 3-dimensional real-time echocardiography. <i>Journal of the American Society of Echocardiography</i> , 2008 , 21, 371-6	5.8	6
4	Rationale and design of the hemodynamic, echocardiographic and neurohormonal effects of istaroxime, a novel intravenous inotropic and lusitropic agent: a randomized controlled trial in patients hospitalized with heart failure (HORIZON-HF) trial. <i>American Journal of Therapeutics</i> , 2008 , 15, 231-40	1	15
3	"Dynamic imaging" (systolic compression) of myocardial bridge visualised by electronic beam computed tomography. <i>Heart</i> , 2007 , 93, 1135	5.1	1
2	Recurrent atrial myxoma. <i>Romanian Journal of Internal Medicine</i> , 2004 , 42, 625-34		
1	Anterolateral papillary muscle rupture: diagnosis and successful treatment (a case report). <i>Echocardiography</i> , 2002 , 19, 143-4	1.5	4